Acurx Pharmaceuticals (ACXP) Expected to Release Quarterly Earnings on Thursday

Acurx Pharmaceuticals (NASDAQ:ACXP) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Acurx Pharmaceuticals to announce earnings of ($0.45) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.15). On average, analysts expect Acurx Pharmaceuticals to post ($2.00) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

Acurx Pharmaceuticals stock opened at $1.06 on Tuesday. The stock’s 50-day moving average is $1.25 and its 200-day moving average is $1.93. The company has a market cap of $5.89 million, a price-to-earnings ratio of -0.39 and a beta of -2.08. Acurx Pharmaceuticals has a 12 month low of $0.95 and a 12 month high of $7.54.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on ACXP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Thursday, October 15th. HC Wainwright restated a “buy” rating on shares of Acurx Pharmaceuticals in a report on Tuesday, September 29th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on therapies designed to address pathogens that are resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, also known as ACX-375, an investigational oral antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile infection.